BUSULFAN 6 mg /ml FRESENIUS INFUSION Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

busulfan 6 mg /ml fresenius infusion

fresenius kabi south africa (pty) ltd - infusion - not indicated - none

Myleran Tablet 2 mg Јордан - Енглески - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

myleran tablet 2 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - busulfan 2 mg - 2 mg

MYLERAN Tablet Саудијска Арабија - Енглески - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

myleran tablet

aspen - busulfan - tablet - 2 mg

BUSULCAN 6 mg/ml Vial Solution Саудијска Арабија - Енглески - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

busulcan 6 mg/ml vial solution

pharmascience inc. - busulfan - solution - 6 mg/ml

Bufacord 60 mg/10 mL Concentrate Solution for Intravenous Infusion Филипини - Енглески - FDA (Food And Drug Administration)

bufacord 60 mg/10 ml concentrate solution for intravenous infusion

accord healthcare limited - philippine barnch office; distributor: accord healthcare limited - philippine barnch office - busulfan - concentrate solution for intravenous infusion - 60 mg/10 ml

Sulbus 60 mg per 10 ml Concentrate for solution for infusion Саудијска Арабија - Енглески - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sulbus 60 mg per 10 ml concentrate for solution for infusion

accord healthcare limited, united kingdom - busulfan - concentrate for solution for infusion - 6 mg/ml,

Busulfex Injection 60 mg (ブスルフェクス点滴静注用60mg) Јапан - Енглески - すりの適正使用協議会 RAD-AR Council, Japan

busulfex injection 60 mg (ブスルフェクス点滴静注用60mg)

otsuka pharmaceutical co., ltd. - busulfan - injection

MABLIN POWDER 1％ (マブリン散1％) Јапан - Енглески - すりの適正使用協議会 RAD-AR Council, Japan

mablin powder 1％ (マブリン散1％)

ohara pharmaceutical co.,ltd. - busulfan - white to yellowish white powder

Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung Немачка - Енглески - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

busulfan koanaa 6 mg/ml konzentrat zur herstellung einer infusionslösung

PYLERA- bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride capsule Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

pylera- bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride capsule

allergan, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - pylera in combination with omeprazole are indicated for the treatment of patients with  helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori   has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to res